CRANBURY, N.J.--(BUSINESS WIRE)--July 12, 2006--Kos Pharmaceuticals, Inc. (Nasdaq:KOSP - News): Kos Pharmaceuticals, Inc. (Nasdaq: KOSP - News) announced today that it has submitted a supplemental New Drug Application for a complete dosage range of Niaspan Caplet Formulation (CF) products for review to the U.S. Food and Drug Administration (FDA). The Company has begun planning for a first quarter 2007 launch of this new product.
